Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer

  • Authors:
    • Maosong Lin
    • Junxing Huang
    • Jiayi Zhu
    • Hongzhang Shen
  • View Affiliations

  • Published online on: October 16, 2013     https://doi.org/10.3892/etm.2013.1350
  • Pages: 1369-1374
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Elevated levels of C‑reactive protein (CRP) have been described as a prognostic factor in various types of human malignancy. In the present study, the prognostic potency of CRP was validated for patients with colorectal cancer (CRC) in order to guide patient management and define high‑risk populations for follow‑up or for therapeutic purposes. The association between the high sensitivity‑CRP (hs‑CRP) levels of a total of 123 patients with CRC and their clinicopathological characteristics was explored. Subsequently, univariate and multivariate analyses were performed to investigate the survival impact of pre‑treatment hs‑CRP levels in this cohort study. Statistically significant correlations between the serum levels of hs‑CRP and lymph node and distant metastasis (P<0.001 and P=0.012, respectively), vascular and perineural invasion (P<0.001 and P<0.001), grades (P=0.022) and clinical stages (P=0.001), but not age and gender (P=0.616 and 0.676, respectively), were found. The five‑year survival rate of patients with elevated (>5.0 mg/l) hs‑CRP levels was demonstrated to be significantly less than that of those in the normal group (≤5.0 mg/l) by applying the Kaplan‑Meier method (13.3 versus 57.0%, log‑rank test P<0.001). Furthermore, following identification as a prognostic factor through using univariate analysis, high levels of hs‑CRP (P<0.001) were validated as an independent prognosticator in CRC in the present study through using multivariate analysis. Pre‑treatment serum CRP levels were associated with advanced and progressed CRC patients, therefore these levels may serve as a potential prognostic marker for CRC patients.
View Figures
View References

Related Articles

Journal Cover

December 2013
Volume 6 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lin M, Huang J, Zhu J and Shen H: Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer. Exp Ther Med 6: 1369-1374, 2013.
APA
Lin, M., Huang, J., Zhu, J., & Shen, H. (2013). Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer. Experimental and Therapeutic Medicine, 6, 1369-1374. https://doi.org/10.3892/etm.2013.1350
MLA
Lin, M., Huang, J., Zhu, J., Shen, H."Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer". Experimental and Therapeutic Medicine 6.6 (2013): 1369-1374.
Chicago
Lin, M., Huang, J., Zhu, J., Shen, H."Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer". Experimental and Therapeutic Medicine 6, no. 6 (2013): 1369-1374. https://doi.org/10.3892/etm.2013.1350